Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark Pharma Plunges 6%; BSE HEALTHCARE Index Down 0.7%
Thu, 7 Nov 11:9

Glenmark Pharma Plunges 6%; BSE HEALTHCARE Index Down 0.7%Image source: Sakorn BernardaSv/www.istockphoto.com

Glenmark Pharma share price has plunged 6% and is presently trading at Rs 1,660.8.

Meanwhile, the BSE HEALTHCARE index is at 44,175.8 (down 0.7%).

Among the top losers in the BSE HEALTHCARE index today are FDC (down 4.4%) and METROPOLIS HEALTHCARE (down 2.8%).

APOLLO HOSPITALS (up 6.1%) and Jubilant Pharmova (up 2.5%) are among the top gainers today.

Over the last one year, Glenmark Pharma has moved up from Rs 755.6 to Rs 1,660.8, registering a gain of Rs 905.2 (up 119.8%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,089.2 to 44,175.8, registering a gain of 57.3% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 220.4%), SUVEN PHARMACEUTICALS (up 126.7%) and Glenmark Pharma (up 119.8%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 79,650.1 (down 0.9%).

The top losers among the BSE Sensex today are Tech Mahindra (down 2.4%) and M&M (down 2.1%). The most traded stocks in the BSE Sensex are Tata Steel and Reliance Ind..

In the meantime, NSE Nifty is at 24,239.1 (down 1.0%). Hindalco and Shriram Transport are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 64,958.7 to 79,650.1, registering a gain of 14,691.4 points (up 22.6%).

Glenmark Pharma Financial Update...

Glenmark Pharma net profit grew 803.0% YoY to Rs 3,402 million for the quarter ended June 2024, compared to a profit of Rs 377 million a year ago. Net sales rose 6.9% to Rs 32,442 million during the period as against Rs 30,361 million in April-June 2023.

For the year ended March 2024, Glenmark Pharma reported 1944.2% decrease in net profit to Rs -18,309 million compared to net loss of Rs 896 million during FY23. Revenue of the company grew 2.0% to Rs 118,131 million during FY24.

The current Price to earnings ratio of Glenmark Pharma, based on rolling 12 month earnings, stands at -30.7.


Equitymaster requests your view! Post a comment on "Glenmark Pharma Plunges 6%; BSE HEALTHCARE Index Down 0.7%". Click here!